Taysha Gene Therapies is racing toward regulatory approval for TSHA-102, their promising gene therapy for Rett syndrome, with key trials completed and compelling long-term data in hand. They’ve secured manufacturing partnerships, navigated market access hurdles, and strengthened their financial runway—positioning themselves for a potential BLA submission by late 2028. Safety remains strong, with no severe adverse events reported, and they’re gearing up to share pivotal interim trial results in early 2027 that could fast-track their path to market.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
